A carregar...

Denosumab for Treatment of Hypercalcemia of Malignancy

CONTEXT: Hypercalcemia of malignancy (HCM) in patients with advanced cancer is often caused by excessive osteoclast-mediated bone resorption. Patients may not respond to or may relapse after iv bisphosphonate therapy. OBJECTIVE: We investigated whether denosumab, a potent inhibitor of osteoclast-med...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hu, Mimi I., Glezerman, Ilya G., Leboulleux, Sophie, Insogna, Karl, Gucalp, Rasim, Misiorowski, Waldemar, Yu, Bennett, Zorsky, Paul, Tosi, Diego, Bessudo, Alberto, Jaccard, Arnaud, Tonini, Giuseppe, Ying, Wendy, Braun, Ada, Jain, Rajul K.
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4154084/
https://ncbi.nlm.nih.gov/pubmed/24915117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2014-1001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!